Compugen Ltd., a leading company in the field of cancer immunotherapy and computational target discovery, has announced that it will be releasing its first quarter 2024 financial results on Monday, May 20, 2024, before the opening of the U.S. financial markets.
The management will be hosting a conference call and webcast at 8:30 AM ET to discuss the financial results and provide a corporate update. Investors and stakeholders can access the live conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. Additionally, a live webcast will be available through Compugen’s website, and a replay will be made available after the call.
Compugen is known for its state-of-the-art predictive computational discovery capabilities which enable the identification of new drug targets and biological pathways for the development of cancer immunotherapies. The company has developed two proprietary product candidates, including COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT for solid tumor treatment.
Furthermore, Compugen has a partnered program called rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody, which is currently in Phase 3 development by AstraZeneca. The TIGIT component of the bispecific antibody is derived from Compugen’s own clinical stage anti-TIGIT antibody, COM902.
With headquarters in Israel and offices in San Francisco, Compugen is actively working on a therapeutic pipeline of early-stage immuno-oncology programs. These programs aim to address various mechanisms of immune resistance, with the most advanced program, COM503, currently in IND enabling studies and licensed to Gilead. COM503 is a high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, potentially inhibiting cancer growth in the tumor microenvironment.
For more information and investor inquiries, please contact Yvonne Naughton, Ph.D., Head of Investor Relations and Corporate Communications at [email protected] or call +1 (628) 241-0071.
Source: Compugen Ltd.
Compugen Ltd., a leading company in the field of cancer immunotherapy and computational target discovery, has announced the release of its first quarter 2024 financial results on Monday, May 20, 2024. The financial results will be made available before the opening of the U.S. financial markets. This announcement signifies the company’s commitment to transparency and providing stakeholders with information regarding its performance.
During the conference call and webcast scheduled for 8:30 AM ET on the same day, the management will discuss the financial results and provide a corporate update. This communication platform allows investors and stakeholders to gain insights into the company’s financial performance and its strategic direction. The live conference call can be accessed by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. Additionally, a live webcast of the conference call will be available through Compugen’s website, allowing participants to tune in remotely. For those unable to participate in real-time, a replay will also be made available after the call, ensuring accessibility for a broader audience.
In terms of market trends, the field of cancer immunotherapy has been experiencing significant growth and advancement in recent years. According to a report by Grand View Research, the global cancer immunotherapy market size is expected to reach $256.50 billion by 2028, with a compound annual growth rate (CAGR) of 9.9% from 2021 to 2028. This growth is driven by factors such as increasing prevalence of cancer, advancements in technology, and the growing demand for personalized medicine.
One key challenge and controversy associated with cancer immunotherapy is the high cost of treatment. While these therapies have shown promising results, they often come with a hefty price tag, limiting accessibility for some patients. Balancing the need for innovation and affordability remains an ongoing debate within the healthcare industry.
As for Compugen specifically, the company has positioned itself as a leader in predictive computational discovery capabilities for cancer immunotherapy. The development of two proprietary product candidates, COM701 (anti-PVRIG antibody) and COM902 (TIGIT targeting antibody for solid tumor treatment), showcases Compugen’s dedication to advancing novel therapies and addressing unmet medical needs.
Compugen has also formed partnerships to further its pipeline of immuno-oncology programs. One notable collaboration is with AstraZeneca for the development of rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody which is currently in Phase 3 development. This partnership highlights the recognition of Compugen’s expertise and the potential of its TIGIT component derived from the company’s own clinical stage anti-TIGIT antibody, COM902.
It is worth noting that Compugen faces competition in the cancer immunotherapy space from other established companies and emerging players. This competitive landscape emphasizes the importance of continued innovation, strategic collaborations, and successful clinical development to stay ahead in the market.
For more information on Compugen and its financial results, investors and stakeholders can contact Yvonne Naughton, Ph.D., Head of Investor Relations and Corporate Communications at [email protected] or call +1 (628) 241-0071.